Company News

Share this article:

GlaxoSmithKline announced that it will form a joint venture with China-based Jiangsu Walvax Biotech Company to develop pediatric vaccines for measles, mumps and rubella in China. GSK is investing $29.7 million in the deal initially, and will invest an additional $10.7 million in 2015, according to a company statement.

EMD Serono Canada tapped Ariad Healthcare to market its probiotic multivitamin Multibionta – the number one selling multivitamin in France and the UK – in Canada. Other partners on the assignment include Rao Barrett & Welsh, Environics and M2 Universal.


This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions